NCT03030378 2026-03-18
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
38 trialsNCT05372614 2026-03-18
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05687110 2026-03-18
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05687136 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05691517 2026-03-18
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06606990 2026-03-18
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04585958 2026-03-17
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03366116 2026-03-09
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT02423057 2026-03-06
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04294628 2026-02-27
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01534598 2026-02-10
FdCyd and THU for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00923806 2026-01-23
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01445509 2026-01-15
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03842228 2025-10-14
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06223542 2025-09-29
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04372641 2025-09-17
Testing the Safety of CB-5339 in Patients With Cancer
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT02070549 2025-02-13
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT02503709 2025-02-10
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT02317874 2023-08-29
Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT02723864 2022-02-08
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00095459 2019-12-17
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01445106 2019-12-17
A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00048334 2019-12-12
Depsipeptide to Treat Thyroid and Other Advanced Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01251926 2019-11-15
EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00678132 2018-07-05
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01120288 2018-07-05
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00117013 2017-07-02
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00678769 2015-11-04
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00091117 2013-12-16
Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00026169 2013-01-10
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
National Cancer Institute (NCI)
Phase 1 Completed
NCT00001341 2008-03-04
A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00001449 2008-03-04
A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00001495 2008-03-04
A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00004988 2008-03-04
Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00055380 2008-03-04
Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00033878 2007-03-28
Study of Noni in Cancer Patients
National Center for Complementary and Integrative Health (NCCIH)
Phase 1 Completed
NCT00006199 2005-06-24
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)
National Center for Research Resources (NCRR)
Phase 1 Unknown